Devices for Age-Related Macular Degeneration
This article was originally published in Start Up
The recent FDA approval of The Pfizer/Eyetech drug Macugen, which is expected to yield $350 million in its first year on the market, has focused attention on the opportunity in age-related macular degeneration. But AMD isn't only a pharmaceutical opportunity. AMD is a disease of the retina, in the back of the eye, and that presents delivery problems that devices can solve. Device companies are developing drug delivery implants, device therapies, borrowed from the cardiovascular industry, and new photodynamic therapies that aim to rival Visudyne, QLT's laser-activated drug for wet AMD.
You may also be interested in...
A research team has identified a way to treat the dry form of advanced age-related macular degeneration, for which no therapy exists to halt the associated vision loss. The team expects to start clinical testing of an antisense compound to address the problem, an accumulation of a type of RNA, by the end of the year.
Visioncare's recent success in getting an FDA advisory panel to change a recommendation is a rare and noteworthy achievement. But the agency could prove to be an even more formidable barrier - and a potential catalyst for change - for the device sector going forward.
One of Israel's most prolific medical device entrepreneurs, Yossi Gross has launched an amazing number of companies in a wide array of clinical spaces. Two years ago, Gross and GlenRock Israel came up with the idea for Rainbow Medical, a new approach to creating companies around the technologies Gross develops. Rainbow is neither quite a venture fund nor a US-style incubator but has aspects of both. Rainbow's point: too many fledgling device companies have to spend their time raising money rather than developing their technology, while the founders have little experience in doing so or in building the company once capital comes in. Rainbow's innovative investment-fund strategy addresses both issues.